PolyMedix to Make Three Presentations of Antibiotic Data at the 49Th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Annual Meeting on Behalf of the American Society of Microbiology (ASM) San Francisco, CA, September 12 - 15, 2009

• Press Release
• Source: PolyMedix, Inc.
• On 8:30 am EDT, Monday September 14, 2009

RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, will make three presentations of clinical and pre-clinical data regarding its PMX-30063 defensin-mimetic antibiotic compound at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The conference, held on behalf of the American Society for Microbiology (ASM) and the Infectious Diseases Society of America (IDSA), will be held in San Francisco, CA, Saturday, September 12 through Tuesday, September 15, 2009.

Related Quotes

Symbol	Price	Change
PYMX.OB	1.01	0.00

{"s" : "pymx.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The three presentations relating to PolyMedix’s antibiotic compounds are as follows:

“Human Safety and Pharmacokinetics of PMX-30063, a small nonpeptidic mimic of the host defense proteins”

Poster session F1-2015/94, Tuesday September 15, 9:00 a.m.

PMX-30063 is a fully synthetic, amphiphilic molecule designed to interact with bacterial membranes and mimic the antimicrobial peptides, disrupting them via purely physical actions. Since most antimicrobials act by interfering biochemically with specific molecular targets, the development of resistance is virtually inevitable; but with a purely physical action on the membrane, resistance to PMX-30063 should be less likely. The preclinical program has demonstrated therapeutic potential, and clinical development of PMX-30063 is underway. This presentation details results of an ascending single-dose intravenous study in twenty-two normal volunteer males.

“Efficacy of PMX-30063 in Experimental Staphylococcal Skin and Skin Structure Infection Models”

Poster session F1-2013/92, Tuesday September 15, 9:00 a.m.

PMX-30063, a synthetic small molecule mimetic of host defense proteins that is currently in clinical development, possesses a distinct mechanism of action, disrupting bacterial cell membranes and is highly active against both [G]ram+ and [G]ram- organisms. This presentation describes a study performed to evaluate the efficacy of PMX-30063 in the mouse subcutaneous abscess (MSCA) and rat granuloma pouch (RGP) infection models.

“Pharmacokinetic-Pharmacodynamic relationships for PMX-30063 in the mouse thigh burden model”

Poster session F1-2014/93, Tuesday September 15, 9:00 a.m.

Small nonpeptidic mimics of host defense proteins demonstrate broad activity against [G]ram+ and [G]ram- organisms. The mimics target bacterial membranes and are associated with a low incidence of bacterial resistance in in vitro mutagenesis assays. This presentation explores efficacy and pharmacokinetic (PK) studies with PMX-30063 conducted in the mouse thigh burden model to determine pharmacodynamic (PD) indices that correlate with efficacy.

PolyMedix’s lead defensin-mimetic antibiotic compound is PMX-30063, currently in Phase I clinical development. On December 10, 2008, PolyMedix announced the results of the first Phase I human clinical study with PMX-30063. The results of that study suggest that it should be possible to achieve clinically therapeutic levels with daily doses of PMX-30063 which are lower than those associated with any adverse effects seen in the single dose study. On June 5, 2009, PolyMedix announced that it had initiated dosing in a second Phase I clinical study with PMX-30063. This Phase IB clinical study will assess the safety of PMX-30063 given repeatedly over a period of several days. The initial indication planned for PMX-30063 is as a treatment for pan-Staphylococcal infections, including MRSA (methicillin-resistant Staphylococcus aureus).

About PolyMedix, Inc.

PolyMedix is a publicly traded emerging biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix’s compounds are based on biomimetics: non-peptide small molecule drug candidates that mimic the activity of proteins. The Company’s antibiotic compounds, including PMX-30063 – small molecule mimetics of human host-defense proteins – have a mechanism of action distinct from those of current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. The Company’s goal is to develop these as rapidly acting antibiotics for serious systemic and local infections. The Company plans to continue the development of polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company’s heptagonist compounds, including PMX-60056, reverse the activity of both heparin and Low Molecular Weight Heparins, with the goal of developing an antagonist drug for LMWHs, and that is safer and easier to use than currently approved therapy for heparin. For more information, please visit PolyMedix on its website at www.polymedix.com.

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause PolyMedix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal”, “potential,” “may,” ”suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements, PolyMedix’s compounds may not enter or successfully complete clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these factors is included in PolyMedix’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

PolyMedix, Inc.
Lona Cornish, 484-598-2340
lcornish@polymedix.com
or
Investors:
Erika Moran
emoran@investorrelationsgroup.com
or
Media:
The Investor Relations Group
Steven Melfi, 212-825-3210
smelfi@investorrelationsgroup.com